Condition (MeSH)
Hypersplenism
ClinicalTrials.gov lists 17 trials for Hypersplenism or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
17 of the 17 trials are tagged with Hypersplenism itself; the rest are tagged with a narrower condition beneath it.
When did Hypersplenism trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 2 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2014 | 1 |
| 2008 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hypersplenism trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Not applicable | 8 |
| Observational | 7 |
How many Hypersplenism trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 4 |
| Completed | 5 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hypersplenism trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Koneti Rao | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
| Zagazig University | 1 |
Which drugs are being tested for Hypersplenism? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Soquelitinib | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Beta Blocker | 1 |
| Apixaban IR | 1 |
| CT scan | 1 |
| BLOOD SAMPLE | 1 |
| Valproic acid, sodium salt | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hypersplenism trials report? (2)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| low serum IgG | 1 | 1 |
| pneumomediastinum | 1 | 1 |
Which publications cover Hypersplenism? (15)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Partial splenic embolization combined with endoscopic therapies and NSBB decreases the variceal rebleeding rate in cirrhosis patients with hypersplenism: a multicenter randomized controlled trial. | Hepatology international | 2021 | Yes |
| Microwave ablation in the spleen for treatment of secondary hypersplenism: a preliminary study. | AJR. American journal of roentgenology | 2011 | Yes |
| Partial splenic embolization for hypersplenism in cirrhosis: a long-term outcome in 62 patients. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2009 | Yes |
| Hypersplenism is related to age of onset of liver disease. | Irish journal of medical science | 2007 | Yes |
| Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients. | European journal of gastroenterology & hepatology | 2005 | Yes |
Showing 5 of 15 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.